NASDAQ
MDNA

Medicenna Therapeutics Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Medicenna Therapeutics Corp Stock Price

Vitals

Today's Low:
$0.3
Today's High:
$0.31
Open Price:
$0.3051
52W Low:
$0.298
52W High:
$0.966
Prev. Close:
$0.31
Volume:
128080

Company Statistics

Market Cap.:
$26.29 million
Book Value:
0.386
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-39.74%
Return on Equity TTM:
-39%

Company Profile

Medicenna Therapeutics Corp had its IPO on 2001-08-27 under the ticker symbol MDNA.

The company operates in the Healthcare sector and Biotechnology industry. Medicenna Therapeutics Corp has a staff strength of 16 employees.

Stock update

Shares of Medicenna Therapeutics Corp opened at $0.31 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.3 - $0.31, and closed at $0.3.

This is a -2.68% slip from the previous day's closing price.

A total volume of 128,080 shares were traded at the close of the day’s session.

In the last one week, shares of Medicenna Therapeutics Corp have slipped by -18.46%.

Medicenna Therapeutics Corp's Key Ratios

Medicenna Therapeutics Corp has a market cap of $26.29 million, indicating a price to book ratio of 1.3961 and a price to sales ratio of 0.

In the last 12-months Medicenna Therapeutics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16436500. The EBITDA ratio measures Medicenna Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Medicenna Therapeutics Corp’s operating margin was 0% while its return on assets stood at -39.74% with a return of equity of -39%.

In Q2, Medicenna Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Medicenna Therapeutics Corp’s PE and PEG Ratio

Forward PE
208.3333
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.1 per share while it has a forward price to earnings multiple of 208.3333 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medicenna Therapeutics Corp’s profitability.

Medicenna Therapeutics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.0116. Its price to sales ratio in the trailing 12-months stood at 0.

Medicenna Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$31.55 million
Total Liabilities
$3.23 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Medicenna Therapeutics Corp ended 2024 with $31.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.55 million while shareholder equity stood at $26.90 million.

Medicenna Therapeutics Corp ended 2024 with $0 in deferred long-term liabilities, $3.23 million in other current liabilities, 100924000.00 in common stock, $-83843000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.62 million and cash and short-term investments were $29.62 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Medicenna Therapeutics Corp’s total current assets stands at $31.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $835000.00 compared to accounts payable of $0 and inventory worth $0.

In 2024, Medicenna Therapeutics Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Medicenna Therapeutics Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.3
52-Week High
$0.966
52-Week Low
$0.298
Analyst Target Price
$6.66

Medicenna Therapeutics Corp stock is currently trading at $0.3 per share. It touched a 52-week high of $0.966 and a 52-week low of $0.966. Analysts tracking the stock have a 12-month average target price of $6.66.

Its 50-day moving average was $0.41 and 200-day moving average was $0.55 The short ratio stood at 0.66 indicating a short percent outstanding of 0%.

Around 2365.1% of the company’s stock are held by insiders while 1356.7% are held by institutions.

Frequently Asked Questions About Medicenna Therapeutics Corp

The stock symbol (also called stock or share ticker) of Medicenna Therapeutics Corp is MDNA

The IPO of Medicenna Therapeutics Corp took place on 2001-08-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$26.04
-0.92
-3.41%
$11.49
0.45
+4.08%
PAVmed Inc (PAVM)
$0.39
-0.1
-20.9%
Sharda Cropchem Ltd (SHARDACROP)
$441.55
-11.4
-2.52%
$1683.05
12.88
+0.77%
GTL LTD. (GTL)
$10.07
-0.52
-4.91%
$262.4
-14.15
-5.12%
$25.4
-1.1
-4.15%
Kforce Inc (KFRC)
$56.84
-0.62
-1.08%
Xpeng Inc (XPEV)
$18.65
0.17
+0.92%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Address

2 Bloor Street West, Toronto, ON, Canada, M4W 3E2